Cargando…
Structure-Antiplatelet Activity Relationships of Novel Ruthenium (II) Complexes: Investigation of Its Molecular Targets
The regulation of platelet function by pharmacological agents that modulate platelet signaling has proven to be a positive approach to the prevention of thrombosis. Ruthenium complexes are fascinating for the development of new drugs, as they possess numerous chemical and biological properties. The...
Autores principales: | Hsia, Chih-Hsuan, Jayakumar, Thanasekaran, Sheu, Joen-Rong, Tsao, Shin-Yi, Velusamy, Marappan, Hsia, Chih-Wei, Chou, Duen-Suey, Chang, Chao-Chien, Chung, Chi-Li, Khamrang, Themmila, Lin, Kao-Chang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6017231/ https://www.ncbi.nlm.nih.gov/pubmed/29470443 http://dx.doi.org/10.3390/molecules23020477 |
Ejemplares similares
-
Antiplatelet Activity of a Newly Synthesized Novel Ruthenium (II): A Potential Role for Akt/JNK Signaling
por: Khamrang, Themmila, et al.
Publicado: (2017) -
Possible Molecular Targets of Novel Ruthenium Complexes in Antiplatelet Therapy
por: Jayakumar, Thanasekaran, et al.
Publicado: (2018) -
A novel ruthenium (II)-derived organometallic compound, TQ-6, potently inhibits platelet aggregation: Ex vivo and in vivo studies
por: Hsia, Chih-Hsuan, et al.
Publicado: (2017) -
Author Correction: A novel ruthenium (II)-derived organometallic compound, TQ-6, potently inhibits platelet aggregation: Ex vivo and in vivo studies
por: Hsia, Chih-Hsuan, et al.
Publicado: (2020) -
Ir-6: A Novel Iridium (III) Organometallic Derivative for Inhibition of Human Platelet Activation
por: Shyu, Ren-Shi, et al.
Publicado: (2018)